- Hims & Hers Health shares are sliding. What’s behind HIMS decline?
HIMS Stock Pulls Back After 50% Monthly Rally
In addition, Hims recently introduced a new subscriber benefits program with partner discounts, adding to expectations that the company is building a broader consumer health ecosystem.
The recent rally was also fueled in part by upbeat Wall Street commentary. Barclays last week maintained its Overweight rating on Hims & Hers and raised its price target to $29 from $25, a move that helped reinforce bullish sentiment around the company’s outlook.
That analyst action came alongside broader optimism tied to Hims & Hers’ expanding weight-loss and wellness strategy.
HIMS RSI Signals Strengthening Momentum After Sharp Rally
Hims & Hers Health’s RSI has mostly remained in the neutral range over the past year, with several brief moves into overbought territory during periods of strong price momentum.
The indicator recently surged toward the overbought threshold after rebounding from oversold levels earlier in the year, suggesting strengthening bullish momentum following a sharp rally.
HIMS Shares Edge Lower Monday Morning
HIMS Price Action: Hims & Hers Health shares were down 3.31% at $23.95 at the time of publication on Monday, according to Benzinga Pro data.
Image: Shutterstock
This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Market News and Data brought to you by Benzinga APIs
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.